3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Investor Presentation (July 2021)
30 slides from 3b Blackbio Dx's investor presentation, Jul 29, 2021
Slide 1: Kilpest India Limited cover letter to BSE
@ {sé KILPEST INDIA LIMITED REGD. OFFICE & FACTORY : 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 INDIA Tel : 91-755 2586536, 2586537 FAX NO. : 91-755 2580438 E-mail : kilpest@bsnl.in Visit us at : www.kilpest.com kilpestbp|@yahoo.co.in * CIN : L24211MP1972PLC001131 July 29, 2021 The Relations
Slide 2: Investor Presentation July 2021
Farmer’s Trusted Agro-Input Partner for 49 Years Reliable and Affordable Healthcare Diagnostic Solutions INVESTOR PRESENTATION July’ 2021
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation t
Slide 4: Financial Performance and Key Highlights
FINANCIAL PERFORMANCE AND KEY HIGHLIGHTS
Slide 5: Performance Highlights – Q1 2021-22
Performance Highlights – Q1 2021-22 38.23% 46.01% KILPEST (Consolidated) Q1 FY22 Q1 FY21 5288.98 3626.37 Net sales 3266.79 5288.98 3266.79 Profit before tax 1958.01 3626.37 Q1F22 1958.01 Q1F21 Profit after tax 1493.57 2719.68 Paid up Equity share capital 750.81 750.81 Revenue PBT Reserves 12455.98 1
Slide 6: Key Highlights - Agrochemicals
Key Highlights - Agrochemicals Impact of COVID-19 ❑ There was a potential loss in the production/sales during the first quarter of FY22. ❑ The sales for the Q1 remain static for agrochemicals due to nationwide lockdown in April-May’21 and events related to COVID-19. ❑ Company continues to focus on P
Slide 7: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides 70 • Bio pesticide 07 • Antibacterials 01 • Bio fungicide 01 • Fungicides 15 • Bio fertilizers 05 • Herbicides 11 • Bio nematicides 01 • Public Health 11 • Public Health 02 • Microfertilizers 02 • Health &
Slide 8: From the house of Kilpest India Ltd.
Since 1972 From the house of Kilpest India Limited, KILPEST INDIA LTD. India’s most trusted agro-chemical brand proudly brings First licensed Molecular Diagnostics (IVD) manufacturing facility in India under Medical Device Rule 2017 ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GEN
Slide 9: Introduction – 3B BlackBio Biotech India Limited
Introduction – 3B BlackBio Biotech India Limited “3B BlackBio Biotech India Limited”, a subsidiary of Kilpest India Limited, embarked on its mission in 2011 with a vision to provide reliable, accurate and affordable healthcare solutions to all. Ever since its inception, 3B BlackBio is engaged in Des
Slide 10: TRUPCR® from 3B BlackBio Biotech (I) Ltd.
TRUPCR® from 3B BlackBio Biotech (I) Ltd. Our Vision: Our Mission: To offer reliable, affordable and To design and develop molecular effective healthcare solutions to all diagnostics products of superior by recognizing the great potential of quality and value that continuously biotechnology to effec
Slide 11: Timeline & Milestones
Timeline & Milestones COVID-19 YEAR GONE GLOBAL TRUPCR® Launching SARS-CoV- Oncopanels 2 Launch of Solid Tumor AML qPCR Extending Menu with ALL Kit Virology & EGFR Public MPN Adding (USFDA- Health KRAS Virology EUA) Entering & Launch of HBV, HCV NGS Panels Oncology & Expanding Geno, HIV Early Human
Slide 12: Growth Canvas
Growth Canvas ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 13: Financial Highlights – Q1 FY 2022
Financial Highlights – Q1 FY 2022 41.90% 3614.31 48.12% 5016.84 2914.70 1874.98 2022 2021 2022 2021 Revenue EBITDA 3604.81 48.25% 2702.27 47.62% 1865.48 1415.42 2022 PBT 2021 2022 PAT 2021 Rs. In Lakhs. *The Sales and Profitability in the first quarter of last year are higher & not comparable with t
Slide 14: Events related to COVID-19
Events related to COVID -19 In the beginning of March 2020, when India started reporting increasing cases of this new virus COVID-19 and we got ourselves into developing the RT- PCR based kit for its testing which was declared by WHO as the gold standard technique to test patient samples for the pre
Slide 15: Business Outlook – Post COVID; Utilization of Funds
Business Outlook – Post COVID Due to COVID-19, nationally and internationally, number of Molecular Diagnostics Labs and manufacturers have increased manifolds, but with COVID-19 infections potentially decreasing now after June 2021, lot of labs might shut down due to non-viability, still there would
Slide 16: Scheme of Amalgamation, Dividend, Proposed NSE Listing
Scheme of Amalgamation The Scheme of Amalgamation has been duly vetted by BSE on 31st May 2021, and the same is uploaded on the website of BSE. With SEBI approval and thereafter filing with NCLT and its approval, the Scheme of Amalgamation would come in force. Your company is working on faster appro
Slide 17: R&D Strategy, Capacity Expansion and NGS
R&D Strategy & Rapid Antigen Business Vertical Company’s continuous focus on the Research and development (R&D) activities is a valuable tool for growing and improving business. R&D involves researching, developing new and improved products, business verticals, and processes and services to fit the
Slide 18: Exports
Exports In 2019-20 our exports were INR 6.55 million yearly and in Year 2020-21, it increased substantially to INR 19.78 million. This year we want to focus on exports, although our products have been well-accepted in more than 20 countries but due to restriction on exports of RT-PCR Kits we have to
Slide 19: Strong Brand Presence
Strong Brand Presence ❑ We have grown ourselves to be a strong brand in the Indian and Global Molecular Diagnostic Market ❑ With our in depth knowledge of research products, we continuously add new products to our portfolio ❑ On field demonstration of products, training of end-users to use the produ
Slide 20: R&D and People
R&D R&D People •Highly educated team of scientist from varied backgrounds •Dedicated teams for respective segments •Separate onco team headed by researchers (Ph.Ds.) from oncology background •Separate team for infectious parameters headed by researchers (Ph.Ds.) from infectious diseases background L
Slide 21: Product QC - Our Strength
Product QC - Our Strength All TRUPCR® products are passed through stringent QC protocols to ensure optimal performance at customer site • QC of raw material • QC of every final lot • Cherrypicked QC of final batch Besides above routine QC practices, Kits are QC checked on respective* real-time cycle
Slide 22: Our Certificates
Our Certificates US FDA EUA COVID-19 Award of RT-PCR Kit Excellence For Leading CDSCO Licensed IVD Company Diagnostic Kits of the year 2020-21 ISO 13485:2016 Certified Company ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 23: Technology Focus
Technology Focus High Volume Cytogenetics Real-Time PCR 3B’s Focus Low Growth High Growth Other Molecular Techniques Mass Spec Hybridization Sanger Sequencing Next Generation Sequencing Low Volume Microarray ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 24: Product Segments
Product Segments ONCOLOGY ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 25: All Inclusive TRUPCR® Products
All Inclusive TRUPCR® Products TRUPCR® range of products offers end-to-end standardized solutions from samples to optimized end-results Nucleic Acid Detection Sample Nucleic Acid Nucleic Acid Extraction & and Management Preparation Amplification Purification Analysis Sample stabilization TRUPCR ® Nu
Slide 26: Global Recognition
Global Recognition ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 27: Growth Drivers
Growth Drivers • Improvement in Indian healthcare industry with high demand in medical tourism • Increasing number of molecular tests being introduced by labs • Evolution of disease profiles. New viruses and cancers are been diagnosed External Growth Drivers • Increase in evidence-based treatments /
Slide 28: National MSME Award 2018
National MSME Award- 2018 by Hon'ble President of India, Shri Ram Nath Kovind. Hon'ble President of India, Shri Ram Nath Kovind on Friday on the occasion of 20th National Technology Day presented the national award for successful commercialization of indigenous technology at Vigyan Bhavan, New Delhi
Slide 29: Outstanding Achievement Award for Excellence in R&D by FMPCCI
Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal. 3B BLACKBIO BIOTECH (I) LTD. Bhopal is awarded with the ‘Outstanding Achievement Award in recognition of excellence in R&D through technology in MSME enterprise category’, during the 4th Outstanding Achievement Award 2016, held o
Slide 30: Jai Hind
JAI HIND ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS